Endometrial human chorionic gonadotropin (hCG) expression is a marker for adequate secretory transformation of the endometrium

A Comparison of Oral Dydrogesterone with Vaginal Progesterone for Luteal-Phase Support in In vitro Fertilization: A Randomized Controlled Trial

Background

The quality of the luteal phase is the most important issue affecting pregnancy outcomes in assisted reproductive technology (ART). Luteal-phase support with the administration of gonadotropin-releasing hormone (GnRH) agonist or progesterone improves the likelihood of pregnancy in ART. Due to disagreements regarding the best pharmaceutical form of progesterone for success of in vitro fertilization (IVF) in ART methods, the present study aimed to compare the clinical efficacy of oral dydrogesterone with vaginal progesterone on the outcome of pregnancy in IVF.

Materials and Methods

This unblinded randomized clinical trial was conducted at the Shahid Beheshti Hospital, Obstetrics and Gynecology Centre in Isfahan, Iran, between june 2021 and September 2021. In total, 126 couples were included in the study. All patients underwent controlled ovarian stimulation and IVF. Patients were randomly divided into two groups (n = 63 per group). After embryo transfer, group I was treated with Cyclogest 400 mg twice daily, and group II was treated with oral Duphaston 10 mg twice daily.

Results

No significant differences were observed between the two groups in terms of the mean endometrial thickness (P = 0.613), the mean number of transferred embryos (P = 0.100), and the number of implanted embryos (P = 0.338). Additionally, no statistically significant differences in the pregnancy rate were detected between the two groups (P = 0.875).

Conclusions

The evidence from this study indicates that Duphaston is as effective as Cyclogest for luteal-phase support.

Two subtypes of surgery-categorized upper-lateral intracavitary pregnancy identified by MRI, a retrospective study

BACKGROUND

The pregnancy outcomes in women with surgery-categorized upper-lateral intracavitary pregnancy (ULIP), previously named angular pregnancy, demonstrate higher heterogeneity than in women with ultrasonography-categorized ULIP. We aimed to use preoperative MRI and correlated clinical characteristics to explore whether the surgery-categorized ULIP comprises obstetric conditions undefined by the current ultrasonography-based diagnostic criteria.

METHODS

This retrospective study involved 28 women with surgically and pathologically confirmed ULIP from January 2016 to July 2022. Two board-certified radiologists, blinded to the patients' information, independently reviewed the MRI images, and determined each MRI feature, including endometrial thickness (EMT) and peri-gestational sac (GS) endometrial interruption. Disagreements were resolved by discussion to achieve a consensus. Based on the cutoff value of EMT (11.5 mm), the patients were divided into above-cutoff EMT (n = 22) and below-cutoff EMT (n = 6) groups.

RESULTS

Two subtypes of surgery-categorized ULIP were identified. Type-I ULIP (n = 22; EMT ≥ 11.5 mm), when compared to the type-II ULIP (n = 6; EMT < 11.5 mm), demonstrated lower incidence of peri-GS endometrial interruption (2/22 [9.1%] vs 6/6 [100%]; P = 0.001), higher logarithmic ß-human chorionic gonadotropin (ß-hCG) concentration (4.7 ± 0.4 mIU/ml vs 4.2 ± 0.6 mIU/ml; P = 0.026), lower rate of repeated dilatation and curettage (1/22 [4.6%] vs 4/6 [66.7%]; P = 0.003), less intraoperative blood loss (10.1 ± 6.3 ml vs 28.3 ± 18.3 ml; P = 0.001), and shorter hospital stay (2.8 ± 1.7 days vs 7.5 ± 3.8 days; P = 0.001). The peri-GS endometrial interruption negatively correlated with EMT (Odds ratio [OR] = 0.55; P = 0.001) and logarithmic ß-hCG concentration (OR = 0.08; P = 0.045). The below-cutoff EMT negatively correlated with ß-hCG concentration (OR = 0.06; P = 0.021).

CONCLUSIONS

Surgery-categorized ULIP comprised two obstetric conditions among which the type-II ULIP, possessing unique imaging features undocumented in the literature, requires further attention during clinical practice.

The Application of the EP9-A Protocol in the Analysis of the Performance of the Immunofluorescence Assay for HCG Detection

Objective

The present study aims to evaluate the comparability of the results of two methodologies for detecting human chorionic gonadotropin (HCG) to assess whether the immunofluorescence method for detecting HCG is adequate for clinical applications.

Methods

Referring to the protocol requirements of the American Clinical Laboratory Standards Institute (CLSI) EP9-A2 (methodological matching and bias assessment with patient samples), we collected 40 fresh serum specimens from our outpatients and inpatients, including 20 specimens with abnormal HCG concentrations (eight samples with different concentration ranges were selected daily and HCG was measured simultaneously with the two testing systems for five consecutive days). The assays were performed on a Dxl 800 fully automated immunoassay analyzer from Beckman Coulter Inc., USA, as a comparative method and on a Jet-iStar 3000 immunoassay analyzer from Zhonghan Shengtai Inc. as an experimental method. Methodological comparison and bias assessment of the results of the two methods for HCG detection were performed. The OLR regression model was used for calculating bias and regression analysis, and Spearman’s rank correlation coefficient was used for correlation analysis. The correlation and comparability of the two systems were calculated based on the results of the analysis.

Results

A good correlation in HCG results in the range of 5–50,000 U/mL was obtained from the two assay systems (r = 0.998) with the regression equation of y = 1.020x + 12.96. The estimated deviation was within the permissible deviation and acceptable.

Conclusion

The results of HCG measurement by the two different assay systems were well correlated and comparable.